RBC Capital raised the firm’s price target on NeueHealth to $8 from $7 and keeps a Sector Perform rating on the shares. The firm is updating its model as it sees the company’s liquidity improving folloing the sale of its California Medicare Advantage business, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NEUE:
- NeueHealth rises 15.3%
- NeueHealth sees FY24 enterprise Adjusted EBITDA $15M-$25M
- NeueHealth reports Q4 revenue $292.87M, consensus $283.44M.
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue